Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agalsidase beta vs agalsidase alfa in male patients with classic Fabry disease
2019-000064-21Phase 4Terminated
- Sponsor
- Sanofi
- Start
- Aug 2019
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of agalsidase beta in Fabry disease (FD) (2 arms), sponsored by Sanofi. Primary endpoint: Change in plasma globotriaosylsphingosine (lyso-GL3) level. Started Aug 2019; status: terminated.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2019-000064-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000064-21.